Overview

• Isolated from a recovered patient, the monoclonal antibodies neutralized mpox in vitro and prevented severe disease and death in rodent models.
• Structural work delivered the first crystal structure of a human antibody bound to an mpox protein, clarifying how the A35 epitope is engaged.
• Blood analyses showed people who recovered from mpox carry high levels of A35-targeting antibodies, correlating with milder illness and no hospitalization.
• The Icahn School of Medicine patented the antibodies and plans advanced preclinical safety and efficacy studies before evaluating them in human trials.
• With no approved mpox treatment after a leading candidate failed in trials, the conserved A35 target offers a promising path for antiviral development.